Drugs - MedicineNews.net - Medical Updates

Search results for "Abilify"

Abilify Maintena, a dopamine D2 partial agonist in once-monthly injectable form, for the maintenance treatment of schizophrenia in adult patients stabilised with oral Aripiprazole

Lundbeck and Otsuka Pharmaceutical have announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) recommending marketing authorisation f ... read article

Cardiometabolic adverse reactions suspected of being associated with second-generation antipsychotics in children and adolescents

Excess weight and obesity in the general population are increasing problems throughout the Western world, and this rise has also been observed in children and adolescents.Weight gain and obesity are k ... read article

Bipolar disorder type 1: Abilify approved for maintenance treatment as an adjunct to either Lithium or Valproate ( 2011 )

The FDA ( Food and Drug Administration ) has approved Abilify ( Aripiprazole ) as an adjunct to the mood stabilizers Lithium or Valproate for the maintenance treatment of bipolar I disorder. Abili ... read article

Pediatric patients: use of antipsychotics associated with significant weight gain

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride l ... read article

Antipsychotic drugs: use of Olanzapine by children and adolescents associated with high weight gain

Focus

Multiple sclerosis: FDA has approved Tecfidera

The FDA ( Food and Drug Administration ) has approved Tecfidera ( Dimethyl fumarate ) capsules to treat adults with relapsing forms of multiple sclerosis.Multiple sclerosis is a chronic, inflammatory, ... read article

Apremilast linked to significant and clinically meaningful improvements for the primary and major secondary endpoint in plaque psoriasis

Celgene has announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase ... read article

Kadcyla, a new treatment for late-stage breast cancer, approved by Food and Drug Administration

The U.S. Food and Drug Administration ) has approved Kadcyla ( Ado-Trastuzumab Emtansine ), a new therapy for patients with HER2-positive, late-stage ( metastatic ) breast cancer.HER2 is a protein inv ... read article

FISSION and NEUTRINO trial: Sofosbuvir has met primary endpoints for hepatitis C

Results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide Sofosbuvir in combination with Ribavirin ( FISSION ) and in combination with Ribavirin ... read article

Increased risk of high-grade prostate cancer with 5-alpha reductase inhibitors

Men aged 55 and over with a normal digital rectal examination and PSA less than or equal to 3.0 ng/mL at baseline taking Finasteride 5 mg/day ( 5 times the dose of Propecia ) in the 7-year Prostate Ca ... read article

Castration-resistant prostate cancer: Cabozantinib linked to high rates of complete or partial bone scan resolution, pain relief, improvements in hemoglobin, and tumor regression

Exelixis has reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer ( CRPC ) treated with Cabozantinib ( XL184; Cometriq ) in an ongoing phase 2 ... read article